Alkermes (NASDAQ:ALKS) Releases FY 2025 Earnings Guidance

Alkermes (NASDAQ:ALKS) issued an update on its FY 2025 earnings guidance on Wednesday morning. The company provided EPS guidance of 1.030-1.210 for the period, compared to the consensus EPS estimate of 1.740. The company issued revenue guidance of $1.3 billion-$1.4 billion, compared to the consensus revenue estimate of $1.4 billion.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on ALKS shares. Stifel Nicolaus raised Alkermes from a “hold” rating to a “buy” rating and increased their price objective for the company from $25.00 to $36.00 in a report on Tuesday, November 5th. Mizuho lifted their price objective on Alkermes from $35.00 to $40.00 and gave the stock an “outperform” rating in a report on Wednesday, November 13th. JPMorgan Chase & Co. reduced their target price on shares of Alkermes from $32.00 to $26.00 and set a “neutral” rating for the company in a research note on Friday, October 25th. HC Wainwright restated a “neutral” rating and issued a $46.00 target price on shares of Alkermes in a report on Thursday. Finally, Piper Sandler reiterated an “overweight” rating and set a $37.00 target price (down from $38.00) on shares of Alkermes in a report on Friday, October 25th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and ten have issued a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $37.08.

Alkermes Stock Up 2.9 %

ALKS traded up $0.96 during midday trading on Thursday, reaching $34.46. The company’s stock had a trading volume of 418,971 shares, compared to its average volume of 1,573,937. The stock’s 50-day moving average is $30.21 and its 200-day moving average is $28.68. Alkermes has a 1 year low of $22.90 and a 1 year high of $34.33. The firm has a market capitalization of $5.57 billion, a price-to-earnings ratio of 17.67, a PEG ratio of 1.83 and a beta of 0.49. The company has a current ratio of 3.45, a quick ratio of 3.03 and a debt-to-equity ratio of 0.22.

Alkermes (NASDAQ:ALKS) last released its earnings results on Wednesday, February 12th. The company reported $0.92 EPS for the quarter, topping the consensus estimate of $0.81 by $0.11. Alkermes had a return on equity of 24.92% and a net margin of 22.15%. As a group, research analysts expect that Alkermes will post 2.23 EPS for the current year.

Insider Buying and Selling at Alkermes

In other news, Director Cato T. Laurencin sold 2,691 shares of the company’s stock in a transaction dated Monday, December 9th. The shares were sold at an average price of $31.85, for a total transaction of $85,708.35. Following the sale, the director now directly owns 23,013 shares in the company, valued at approximately $732,964.05. This represents a 10.47 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Craig C. Hopkinson sold 100,918 shares of the stock in a transaction dated Thursday, January 30th. The shares were sold at an average price of $32.05, for a total transaction of $3,234,421.90. Following the completion of the transaction, the executive vice president now directly owns 44,290 shares of the company’s stock, valued at approximately $1,419,494.50. The trade was a 69.50 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 179,189 shares of company stock worth $5,723,518 in the last quarter. 4.89% of the stock is owned by corporate insiders.

Alkermes Company Profile

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.